NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 309 filers reported holding NOVOCURE LTD in Q1 2022. The put-call ratio across all filers is 1.53 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $13,323,087 | -60.7% | 824,959 | +0.9% | 0.01% | -58.8% |
Q2 2023 | $33,936,045 | -35.7% | 817,736 | -6.8% | 0.03% | -35.8% |
Q1 2023 | $52,784,156 | -25.0% | 877,688 | -8.6% | 0.05% | -29.3% |
Q4 2022 | $70,419,374 | -14.1% | 960,046 | -11.0% | 0.08% | -17.6% |
Q3 2022 | $81,990,000 | +9.2% | 1,079,096 | -0.1% | 0.09% | +16.7% |
Q2 2022 | $75,076,000 | -33.5% | 1,080,236 | -20.7% | 0.08% | -19.6% |
Q1 2022 | $112,924,000 | +10.5% | 1,362,983 | +0.1% | 0.10% | +79.6% |
Q4 2021 | $102,208,000 | -36.4% | 1,361,323 | -1.7% | 0.05% | -39.3% |
Q3 2021 | $160,820,000 | -42.9% | 1,384,351 | +9.0% | 0.09% | -40.3% |
Q2 2021 | $281,602,000 | +30.5% | 1,269,504 | -22.3% | 0.15% | +34.2% |
Q1 2021 | $215,832,000 | -17.1% | 1,632,851 | +8.5% | 0.11% | -12.6% |
Q4 2020 | $260,505,000 | +34.6% | 1,505,459 | -13.4% | 0.13% | +7.6% |
Q3 2020 | $193,510,000 | +41.5% | 1,738,470 | -24.6% | 0.12% | +20.4% |
Q2 2020 | $136,767,000 | +57.4% | 2,306,360 | +78.7% | 0.10% | +30.7% |
Q1 2020 | $86,902,000 | +6.7% | 1,290,492 | +33.5% | 0.08% | +27.1% |
Q4 2019 | $81,481,000 | +9.1% | 966,898 | -3.2% | 0.06% | -6.3% |
Q3 2019 | $74,657,000 | -19.2% | 998,371 | -31.6% | 0.06% | -22.2% |
Q2 2019 | $92,353,000 | +38.7% | 1,460,587 | +5.7% | 0.08% | +32.8% |
Q1 2019 | $66,562,000 | +33.7% | 1,381,810 | -7.1% | 0.06% | +17.3% |
Q4 2018 | $49,803,000 | +0.5% | 1,487,571 | +57.3% | 0.05% | +18.2% |
Q3 2018 | $49,552,000 | +213.4% | 945,654 | +87.2% | 0.04% | +175.0% |
Q2 2018 | $15,811,000 | +712.5% | 505,111 | +465.6% | 0.02% | +700.0% |
Q1 2018 | $1,946,000 | +88.6% | 89,302 | +74.9% | 0.00% | +100.0% |
Q4 2017 | $1,032,000 | -22.1% | 51,047 | -23.5% | 0.00% | 0.0% |
Q3 2017 | $1,324,000 | +108.5% | 66,711 | +81.8% | 0.00% | 0.0% |
Q2 2017 | $635,000 | +222.3% | 36,694 | +50.3% | 0.00% | – |
Q1 2017 | $197,000 | -37.5% | 24,414 | -39.4% | 0.00% | – |
Q4 2016 | $315,000 | +23.5% | 40,262 | +34.6% | 0.00% | – |
Q3 2016 | $255,000 | -31.1% | 29,908 | -5.6% | 0.00% | – |
Q2 2016 | $370,000 | – | 31,675 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |